Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.

Also called NCT04602754

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 228 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT04602754
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04602754. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (actual); primary completion 2026-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
Condition
Dyslipidemia Associated With Type II Diabetes Mellitus
Intervention (Drug)
BERLIM 25/20 ASSOCIATION
Intervention (Other)
EMPAGLIFLOZIN PLACEBO
Intervention (Other)
ROSUVASTATIN CALCIUM PLACEBO
Intervention (Drug)
EMPAGLIFLOZIN
Intervention (Drug)
ROSUVASTATIN CALCIUM
Intervention (Other)
BERLIM 25/20 ASSOCIATION PLACEBO
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct04602754
Content hash
94de2a8a248710a6758dab73a04b85241c45341298dcdb3b57db4892d0fa8954